Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Incyte
Incyte
Eli Lilly, Incyte Report Positive Results For Baricitinib In Alopecia Areata Treatment
Eli Lilly, Incyte Report Positive Results For Baricitinib In Alopecia Areata Treatment
NASDAQ
Eli Lilly
Incyte
baricitinib
alopecia areata
Flag link:
FDA to quickly review Incyte’s Jakafi in chronic GVHD
FDA to quickly review Incyte’s Jakafi in chronic GVHD
Pharmaforum
FDA
Incyte
Jakafi
graft vs host disease
Flag link:
Incyte Says FDA Grants Priority Review For Eczema Cream
Incyte Says FDA Grants Priority Review For Eczema Cream
Yahoo/SmarterAnalyst
Incyte
eczema
FDA
priority review
ruxolitinib
Flag link:
What's Behind Incyte's Better-Than-Expected Q4 Earnings
What's Behind Incyte's Better-Than-Expected Q4 Earnings
Motley Fool
Incyte
earnings
Flag link:
Incyte makes bid to join the checkpoint inhibitor club
Incyte makes bid to join the checkpoint inhibitor club
Pharmaforum
Incyte
FDA
retifanlimab
anal cancer
HIV
HPV
Flag link:
Incyte lands priority review for PD-1 inhibitor in anal cancer
Incyte lands priority review for PD-1 inhibitor in anal cancer
Fierce Biotech
Incyte
FDA
priority review
anal cancer
retifanlimab
Flag link:
JPM: Established relationships were key to pandemic drug launches, Incyte CEO says
JPM: Established relationships were key to pandemic drug launches, Incyte CEO says
Fierce Pharma
COVID-19
pandemic
drug launches
Incyte
JPMHC 2021
Flag link:
Novartis/Incyte draw blank with Jakafi in COVID-19
Novartis/Incyte draw blank with Jakafi in COVID-19
Pharmaforum
Novartis
Incyte
Jakafi
COVID-19
clinical trials
Flag link:
EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis
EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis
Yahoo
Eli Lilly
Incyte
baricitinib
atopic dermatitis
EADV
Flag link:
Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time
Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time
Marketwatch
Eli Lilly
Incyte
olumiant
COVID-19
remdesivir
Gilead Sciences
Flag link:
Karuna and Incyte scrap programs; More cash for the SPACs
Karuna and Incyte scrap programs; More cash for the SPACs
Endpoints
Karuna Therapeutics
Eli Lilly
Incyte
SPAC
Flag link:
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
MedCity News
FDA
Monjuvi
CAR-T
MorphoSys
Incyte
diffuse large B-cell lymphoma
Flag link:
Ruxolitinib passes another PhIII test for graft-versus-host disease, a win for Incyte and Novartis
Ruxolitinib passes another PhIII test for graft-versus-host disease, a win for Incyte and Novartis
Endpoints
ruxolitinib
Novartis
Incyte
graft vs host disease
Flag link:
Why Incyte's Q1 Loss Isn't As Bad As It Looks
Why Incyte's Q1 Loss Isn't As Bad As It Looks
Motley Fool
Incyte
earnings
Flag link:
#AACR20: Early data suggest Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions
#AACR20: Early data suggest Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions
Endpoints
Novartis
Incyte
AACR
lung cancer
MET inhibitors
capmatinib
Flag link:
Novartis, Incyte's Jakafi boosts its case in graft-versus-host disease with another phase 3 win
Novartis, Incyte's Jakafi boosts its case in graft-versus-host disease with another phase 3 win
Fierce Pharma
Novartis
Incyte
Jakafi
clinical trials
COVID-19
cytokine storm
graft vs host disease
Flag link:
Incyte nabs 2nd ever approval ahead of schedule as FDA insists it can still review on time
Incyte nabs 2nd ever approval ahead of schedule as FDA insists it can still review on time
Endpoints
Incyte
Pemazyre
pemigatinib
bile duct cancer
cholangiocarcinoma
FDA
Flag link:
Incyte, Novartis launch drug study to treat coronavirus complication
Incyte, Novartis launch drug study to treat coronavirus complication
Marketwatch
Incyte
Novartis
cytokine storm
COVID-19
clinical trials
Jakafi
Flag link:
Incyte to Test Its Cancer Drug Jakafi as a Treatment for COVID-19
Incyte to Test Its Cancer Drug Jakafi as a Treatment for COVID-19
Motley Fool
cancer
COVID-19
Incyte
Jakafi
Flag link:
Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata
Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata
Pharmaceutical Business Review
Eli Lilly
Incyte
breakthrough therapy
FDA
baricitinib
alopecia areata
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »